NCT04030429 is a Phase 2 clinical trial of Crizotinib 250 MG in Endometrial Cancer Recurrent, sponsored by National Cheng-Kung University Hospital.

Who is sponsoring NCT04030429?

NCT04030429 is sponsored by National Cheng-Kung University Hospital.

What drugs are being tested in NCT04030429?

Interventions in NCT04030429: Crizotinib 250 MG.

What condition does NCT04030429 study?

NCT04030429 studies Endometrial Cancer Recurrent.

Is NCT04030429 still recruiting?

NCT04030429 is currently terminated. Last updated 16 July 2025.

Last reviewed 2025-07-16 · How we verify

NCT04030429

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Terminated Phase 2 Last updated 16 July 2025

What this trial tests

Phase 2 trial testing Crizotinib 250 MG in Endometrial Cancer Recurrent in 40 participants. Terminated before completion.

Timeline

1 September 2019

Primary endpoint
1 June 2025

1 June 2025

Quick facts

Lead sponsor	National Cheng-Kung University Hospital
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 September 2019
Primary completion	1 June 2025
Estimated completion	1 June 2025
Sites	1 location across Taiwan

Drugs / interventions tested

Crizotinib 250 MG — full drug profile →

Conditions studied

Endometrial Cancer Recurrent — all drugs for Endometrial Cancer Recurrent →

Sponsor

National Cheng-Kung University Hospital

Who can join

Adults 20 to 75, any sex, with Endometrial Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The majority of endometrial cancer patients with disease spread beyond the uterus will progress within 1 year. Platinum-based chemotherapy was used as the first-line treatment in metastatic or advanced endometrial cancer. There is no standard protocol for the second-line option when tumors persist or recur. In vitro and in vivo studies showed Crizotinib, an approved drug for the treatment of ALK-positive non-small cell lung cancer, demonstrated activities in endometrial cancer with c-MET kinase and Sema domain mutations. As a consequence, a phase 2 clinical trial to investigate the efficacy of Crizotinib in endometrial cancer patients with MET mutation is initiated.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer.
Megino-Luque C, Moiola CP, Molins-Escuder C, López-Gil C, et al · · 2020 · cited 17× · PMID 32987790 · DOI 10.3390/cancers12102751
<i>MET</i> Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer.
Yeh YM, Wu PY, Lin PC, Su PF, et al · · 2021 · cited 4× · PMID 34439385 · DOI 10.3390/cancers13164231

Verify or expand the search:

Other trials of Crizotinib 250 MG

Trials testing the same drug.

NCT04423185 — PLATFORM Study of Precision Medicine for Rare Tumors · Phase 2 · recruiting
NCT04322890 — Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation · Phase 2 · recruiting

Other recruiting trials for Endometrial Cancer Recurrent

Currently open trials in the same condition.

NCT06781151 — A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB · recruiting
NCT03621904 — PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer · recruiting
NCT05410717 — CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1 · recruiting

Other National Cheng-Kung University Hospital trials

Trials by the same sponsor.

NCT07525713 — Virtual Reality Mirror Therapy With Focused Object-Directed Attention System · NA · not yet recruiting
NCT07369271 — Continuous Cervical Erector Spinae Plane Block Versus Interscalene Nerve Block in Shoulder Arthroscopic Surgery · NA · not yet recruiting
NCT07262411 — Peer-based Recovery Program · NA · not yet recruiting
NCT07257926 — Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Contr · Phase 4 · not yet recruiting
NCT07269132 — Applying the ADDIE Model to Develop a Multimedia Program to Enhance Chemotherapy Knowledge and Self-Efficacy Among Inten · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04030429 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cheng-Kung University Hospital
Last refreshed: 16 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04030429.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing